The karyotype in secondary hematologic disorders after treatment for Hodgkin's disease. A study of 19 patients

Cancer Genet Cytogenet. 1988 Dec;36(2):165-72. doi: 10.1016/0165-4608(88)90140-9.

Abstract

In 19 cases of secondary hematologic disorders in patients previously treated for Hodgkin's disease, chromosome aberrations were analyzed in relation to the type of previous chemo- and/or radiotherapy, age of the patients, histopathologic features of the Hodgkin's disease at diagnosis, time interval between the treatment and the occurrence of the secondary disorder, and survival. The karyotype was of significant prognostic value when three cytogenetic groups were considered: patients with normal karyotypes; patients with aberrations of chromosome 7 as the sole anomaly; and patients with complex rearrangements and translocations. The last group showed the lowest rate of survival. Bone marrow transplantation was successful in two patients with a normal karyotype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosome Aberrations*
  • Female
  • Hodgkin Disease / drug therapy
  • Hodgkin Disease / radiotherapy
  • Hodgkin Disease / therapy*
  • Humans
  • Karyotyping
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Radiation-Induced / genetics*
  • Male
  • Mechlorethamine / administration & dosage
  • Mechlorethamine / adverse effects
  • Middle Aged
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / genetics*
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Procarbazine / administration & dosage
  • Procarbazine / adverse effects
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Prednisone

Supplementary concepts

  • MOPP protocol